Listing 3 - Actual negotiations

Indication:

For the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least three prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody, and have demonstrated disease progression on or after the last therapy.

Indication:

Prurigo nodularis

Indication:

For the treatment of moderate-to-severe atopic dermatitis (AD) in patients aged 12 years and older who are candidates for systemic therapy.

Indication:

Nonsegmental vitiligo

Indication:

Indicated as an add-on maintenance treatment in adult patients with chronic obstructive pulmonary disease (COPD) characterized by raised blood eosinophils inadequately controlled by the combination of an inhaled corticosteroid (ICS), a long-acting beta2-agonist (LABA), and a long-acting muscarinic antagonist (LAMA), or on a combination of a LABA and a LAMA if ICS is not appropriate.

Indication:

Severe chronic rhinosinusitis with nasal polyps

Indication:

Prurigo nodularis

Indication:

Atopic dermatitis, pediatrics

Indication:

Keytruda (pembrolizumab), for the treatment of adult patients with muscle-invasive bladder cancer (MIBC) who are ineligible for cisplatin containing chemotherapy, in combination with enfortumab vedotin (Padcev), as neoadjuvant treatment and then continued after radical cystectomy as adjuvant treatment.

Indication:

Early breast cancer, Metastatic breast cancer, Metastatic gastric cancer